Healthcare / Drug Manufacturers - Specialty & GenericTaipei Exchange
$45.90
+1.20 (+2.74%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-189.7M · quality 69.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.6B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-41.4%
↓Gross Margin
N/A
•Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.87x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-407.2M · FCF $-353.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $-407.2M | $-407.2M | $-192.2M | $-85.3M | $-43.8M |
| EBITDA | $-404.7M | $-404.7M | $-190.8M | $-84.5M | $-43.1M |
| EPS | — | — | -4.50 | -6.82 | -0.53 |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | — | — |
| Current Ratio | 32.42 | 32.42 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-353.8M | $-353.8M | $-189.7M | $-78.0M | $-44.2M |
| Returns | |||||
| ROE | -41.4% | -41.4% | -30.7% | -25.4% | -246.9% |
| Valuation | |||||
| P/B | 4.64 | 4.64 | — | — | — |
| Growth & Yield | |||||
| EPS Growth | — | — | 34.1% | -1196.3% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+25.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-4.50 → n/d
Residual
+25.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.